Hong Kong's Akeso has ended the week on a high note, with an FDA approval for its PD-1 inhibitor penpulimab and more data on PD-1/VEGF bispecific antibody ivonescimab. Penpulimab has picked up a ...

PD-1, VEGFA, and CTLA-4 are clinically validated targets for immunotherapies, which can exert complementary, multi-dimensional anti-tumor effects through synergistic mechanisms. Blockade of PD-1 ...

Sensei Biotherapeutics reports promising clinical data in PD-(L)1-resistant cancer patients, with cash to fund operations through Q2 2026. Sensei Biotherapeutics, Inc. announced promising clinical ...

This part of the Phase II study evaluates eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first line ...

HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with ...